Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
UTD2 is the world's first oral epothilone microtubule inhibitor
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
Construction will begin this year with the new capacity anticipated by 2025
Subscribe To Our Newsletter & Stay Updated
